Feature | Radiation Therapy | July 06, 2020 | By Yves Archambault

Adaptive Therapy Today

An in-depth look at how the emerging treatment is improving with a new standard

Radiotherapy has been used to treat cancers for more than a century and continues to be utilized in cancer treatment plans today. Since the introduction of radiotherapy, clinicians have been working tirelessly to further refine treatments to better target cancer.

Everything has room for improvement, right? Right. When it comes to cancer care, it is no different. Researchers, drug companies and technology innovators are constantly working to improve efficiency and efficacy, racing to create the best and most far-reaching cancer treatments. Significant resources are being dedicated to a rapidly evolving form of cancer therapy that is designed to be more effective than other existing options. However, new innovations have introduced new challenges, and emerging treatments must adapt to overcome these barriers. 

Adaptive Therapy’s Current Standard Implementation Process

Radiotherapy has been used to treat cancers for more than a century and continues to be utilized in cancer treatment plans today. Since the introduction of radiotherapy, clinicians have been working tirelessly to further refine treatments to better target cancer. One of today’s leading-edge cancer treatments is adaptive radiation therapy, as it proactively adjusts and evolves over time to respond to day-to-day changes in the tumor and the patient’s anatomy, adjusting to better target the cancer and avoid healthy tissues. This treatment has been dubbed the “holy grail” of radiotherapy due to the notable improvements seen with regards to tumor control as a result of long-term clinical adaptive therapy sessions. Adaptive therapy is particularly beneficial for the treatment of head and neck cancers, and cancers below the respiratory system, including bladder cancer. 

In order to understand where the industry is headed and discuss current solutions, we have to first assess where we have been. For some time, adaptive therapy relied on MR-linac systems, integrating an MR scanner with a linac to allow clinicians to better picture the target during treatments. In the past few years, this approach has involved hours of training, longer treatment delivery sessions and skilled clinician hours to support the end-to-end process. To ensure clinicians are maximizing their time and resources with patients, the industry remains hyper-focused on introducing highly intuitive treatment tools that prioritize patient comfort and experience.  

Ultimately, it is up to clinics to procure and implement new technology. With the way that adaptive therapy is currently set up in the few hospitals where it is available, the equipment requires significant modifications to existing radiotherapy rooms that are complex and take time to complete. On top of that, it demands significant capital. The high price point restricts the number of clinics that can implement adaptive therapy, thus limiting the number of patients whom have access to the treatment. 

While adaptive therapy can adapt to daily changes in the patient, to truly advance, it needs to adapt to today’s environment and challenges.   

A Look at the Patient Experience 

Adaptive therapy has shown promise with various cancers, including bladder cancer, to increase the tumor control probability. That said, there is room for improvement, especially with regard to scalability. Traditionally, adaptive therapy would exclude patients with surgical clips and certain metal pieces in their body, as they cannot be treated with an MR-linac. Beyond this, things like treatment duration and comfort must be acknowledged.

Patient experience must be taken into consideration and improved upon when implementing advancements around adaptive therapy.

Emerging Treatments: Meeting Today’s Challenges 

Across industries, intelligent treatment technologies are being deployed with different goals in mind. What are those main goals? Maximize the number of patients treated each and every day. Smart technologies can help minimize clinical treatment time and in turn treat more patients. Going hand-in-hand with this, advancing technology so that it is more intuitive and easier to learn will ensure that skilled clinicians’ hours are used resourcefully and that they have time to treat more patients. Shortening training time will expedite the onboarding process and provide patient access faster than ever before. Shaving minutes from treatment, while sustaining effectiveness, will free up time and valuable resources for all parties. 

A more cost-effective solution has the potential to make adaptive therapy more accessible to clinics both large and small, and thereby open doors to patients across the world. Historically, adaptive requires highly skilled clinicians to devote more time to therapy than with other approaches. Making this technology more intuitive through emerging artificial intelligence (AI) and machine learning (ML) techniques allows clinicians to make educated, and informed, decisions in a shorter period. 

While some have alluded to AI overtaking skilled positions, it is almost certain that clinicians will use emerging AI and ML technology as a supportive tool, to streamline processes and act faster. Automating this part of the manual labor in adaptive therapy will reduce cognitive load and is aimed at facilitating better decision making.  

The Road to Success: What This Means for Patients 

Welcoming clinician and patient feedback, conducting additional clinical research on challenges and opportunities, and taking a good look at emerging AI and ML all will be driving factors to evolving adaptive therapy to address today’s challenges. As new technology and discoveries drive cancer research forward, it is ultimately the patients that motivate the industry to push further. 

Radiation therapy is indicated for 50 to 60 percent of cancer patients. Effective and efficient adaptive therapy has the potential to be a breakthrough for radiation treatment, leading us to a more personalized approach — but it is only the beginning. Through collaboration and further refinement, adaptive can reach its full potential for the thousands of patients whose lives depend on it. As the industry continues to innovate, it will open the door to more opportunities, research and groundbreaking advancements in cancer treatment.

 

Yves Archambault is a strategic initiative director at Varian, where he leads the charge of advancements in adaptive therapy through intelligent, accessible technological developments. Archambault focuses bringing together technology, data, process and people to make the most complex radiotherapy solutions accessible and appealing to as many clinics as possible around the world.

Related Content

Recommendations address patient selection and treatment techniques for locally advanced disease

Getty Images

News | Radiation Therapy | October 22, 2020
October 22, 2020 — A new ...
On Oct. 21, Seema Verma, administrator of the Centers for Medicare & Medicaid Services, tweeted that CMS will delay the Radiation Oncology Model’s launch from Jan. 1 to July 1 

Getty Images

News | ASTRO | October 22, 2020
October 22, 2020 — In response to the Oct.
Ezra, a NY-based startup transforming early cancer screening using magnetic resonance imaging (MRI), announced that it has received FDA 510(k) premarket authorization for its Artificial Intelligence, designed to decrease the cost of MRI-based cancer screening, assisting radiologists in their analysis of prostate MRI scans. It is the first prostate AI to be cleared by the FDA.
News | Artificial Intelligence | October 20, 2020
October 20, 2020 — Ezra, a NY-based startup transforming early cancer screening using...
Rebrand reflects Volpara Health's mission to prevent advanced-stage breast cancer
News | Breast Imaging | October 19, 2020
October 19, 2020 — Volpara Solutions, a leader in AI-powered breast density assessment, announced that it has changed
Moffitt Cancer Center researchers are developing a noninvasive, accurate method to analyze a patient's tumor mutations and biomarkers to determine the best course of treatment.

Getty Images

News | Lung Imaging | October 19, 2020
October 19, 2020 — Personalized treatment options for patients with...
Varian, a leading provider of cancer care technologies and solutions, continues to reinforce its commitment to delivering Intelligent Cancer Care during the 2020 American Society for Radiation Oncology (ASTRO) taking place virtually Oct. 24-31.
News | ASTRO | October 19, 2020
October 19, 2020 — ...
Mevion Medical Systems announced that it has shipped the accelerator module for the Mevion S250i Proton Therapy System to Kunshan, China. The 15-ton compact accelerator, the heart of the proton therapy system, is the smallest of its kind and will be the first in China.

Mevion's compact accelerator module is lifted and placed on a truck for the first leg of its journey to China. (Photo: Business Wire)

News | Proton Therapy | October 16, 2020
October 16, 2020 — Mevion Medical Systems announced that it has shipped the accelerator module for the...
Conducted by the University of Gothenburg, Lund University and the University of South Australia, the preclinical study found that dietary oat bran can offset chronic gastrointestinal damage caused by radiotherapy, contradicting long-held clinical recommendations.

Getty Images

News | Radiation Therapy | October 07, 2020
October 7, 2020 — Loved or hated, the humble oat could be the new superfood for cancer patients as international ...
Microscopic photo of a professionally prepared slide demonstrating breast tissue with ductal carcinoma in situ (DCIS). Immuhistochemistry of estrogen receptor positive. Micrograph of breast cancer. Slide shows corresponding length of 1 mm.

Microscopic photo of a professionally prepared slide demonstrating breast tissue with ductal carcinoma in situ (DCIS). Immuhistochemistry of estrogen receptor positive. Micrograph of breast cancer. Slide shows corresponding length of 1 mm. Getty Images

News | Breast Imaging | October 05, 2020
October 5, 2020 — A major study of women with ductal carcinoma in situ (...